At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 67 enrolled
Drug / intervention
Deucravacitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multi-center Extension Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Crohn's Disease or Moderate to Severe Ulcerative Colitis
In Brief
A Phase 2 clinical trial evaluating Deucravacitinib for Crohn Disease and Ulcerative Colitis. Completed, enrolled 67 participants across 43 sites in 16 countries.
Detailed Summary
The purpose of this study is to evaluate the long-term safety and efficacy of Deucravacitinib in participants who have previously been enrolled in a Deucravacitinib Phase 2 study for moderate to severe Crohn's disease or moderate to severe Ulcerative Colitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn Disease, Ulcerative Colitis
CountriesAustralia, Canada, China, Germany, Hungary, Italy, Japan, Netherlands, Poland, Portugal, Romania, Russia, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartMay 2021
Primary CompletionAug 2023
TodayJul 2026
First PostedMay 7, 2021
Enrollment StartMay 7, 2021
Primary CompletionAug 29, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.2 years ago
Interventions
Deucravacitinibdrug
Specified dose on specified days